GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galecto Inc (NAS:GLTO) » Definitions » Asset Turnover

Galecto (Galecto) Asset Turnover : 0.00 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Galecto Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Galecto's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Galecto's Total Assets for the quarter that ended in Dec. 2023 was $44.14 Mil. Therefore, Galecto's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Galecto's annualized ROE % for the quarter that ended in Dec. 2023 was -74.30%. It is also linked to ROA % through Du Pont Formula. Galecto's annualized ROA % for the quarter that ended in Dec. 2023 was -58.68%.


Galecto Asset Turnover Historical Data

The historical data trend for Galecto's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galecto Asset Turnover Chart

Galecto Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial - - - - -

Galecto Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Galecto's Asset Turnover

For the Biotechnology subindustry, Galecto's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galecto's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galecto's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Galecto's Asset Turnover falls into.



Galecto Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Galecto's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0/( (73.188+38.227)/ 2 )
=0/55.7075
=0.00

Galecto's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=0/( (50.049+38.227)/ 2 )
=0/44.138
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Galecto  (NAS:GLTO) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Galecto's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-25.9/34.8565
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-25.9 / 0)*(0 / 44.138)*(44.138/ 34.8565)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*1.2663
=ROA %*Equity Multiplier
=-58.68 %*1.2663
=-74.30 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Galecto's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-25.9/44.138
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-25.9 / 0)*(0 / 44.138)
=Net Margin %*Asset Turnover
= %*0
=-58.68 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Galecto Asset Turnover Related Terms

Thank you for viewing the detailed overview of Galecto's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Galecto (Galecto) Business Description

Traded in Other Exchanges
N/A
Address
Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis-related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
Executives
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Bertil Lindmark officer: Chief Medical Officer C/O GALECTO, INC., OLE MAALOES VEJ 3, COPENHAGEN N G7 DK-2200
Hans T. Schambye director, officer: Chief Executive Officer C/O GALECTO, INC., OLE MAALOES VEJ 3, COPENHAGEN N G7 DK-2200
Stephanie Oestreich officer: Chief Business Officer 75 STATE STREET, SUITE 100, BOSTON MA 02109
Jonathan Freve officer: Chief Financial Officer C/O SPRING BANK PHARMACEUTICALS, INC., 113 CEDAR STREET, STE S-7, MILFORD MA 01757
Garrett Winslow officer: General Counsel 35 PARKWOOD DRIVE, C/O SPRING BANK PHARMACEUTICALS, INC., HOPKINTON MA 01748
Anne Prener director C/O RUBIUS THERAPEUTICS, 399 BINNEY STREET SUITE 300, CAMBRIDGE MA 02139
Dallas Jayson Donald Alexander director AIMMUNE THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Chau Quang Khuong director, 10 percent owner C/O ORBIMED ADVISORS, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Stephan Christgau director C/O CASTLE & MORGAN HOLDINGS, INC., 425 MARKET STREET, SUITE 2230, SAN FRANCISCO CA 94105
Soren Moller director C/O NOVO HOLDINGS A/S, TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Anders Pedersen officer: Chief Operating Officer C/O GALECTO, INC., OLE MAALOES VEJ 3, COPENHAGEN N G7 DK-2200
Orbimed Advisors Israel Ii Ltd director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Israel Gp Ii, L.p. director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022

Galecto (Galecto) Headlines